Ark Invest CEO Cathie Wood has a reputation as the queen of investing in businesses with the chutzpah to try and disrupt their industries via cutting-edge innovations. Recently, she has been buying up a trio of biotech stocks left and right. All three are admittedly on the riskier side.

But there's reason to believe that these biotechs might be worthwhile for investors with a slightly lower risk tolerance than Wood's. Let's sift through her recent trades to see if these stocks might be up your alley, or too ambitious to touch.

With a total of eight separate purchases between Jan. 22 and Jan. 29 alone, Cathie Wood has been an enthusiastic buyer of shares in Ginkgo Bioworks Holdings (NYSE: DNA).

Continue reading

Source Fool.com